挪威脑肿瘤质量登记真实世界数据揭示胶质母细胞瘤患者生存的区域差异
研究基于挪威癌症登记2019–2023年1158例组织学确诊的成人胶质母细胞瘤真实世界数据,比较四大区域的手术治疗率与标准化生存。18–70岁患者治疗与生存无显著区域差异,全国中位标准化生存14.4个月;71–89岁老年患者中北部早期死亡率更高、中位标准化生存4.5个月低于全国7.7个月。
要点
- 18–70岁胶质母细胞瘤患者治疗与生存无显著区域差异。
- 老年患者北部术后放化疗使用较少,早期死亡率偏高。
- 北部老年患者生存6个月后与其他区域生存概率相当。
核心结论
- 北部胶质母细胞瘤生存较低与老年患者早期死亡率较高相关,可能因选择较虚弱患者手术且后续较少接受抗肿瘤治疗。
研究设计与样本
- 分析挪威癌症登记2019–2023年1158例组织学确诊成人胶质母细胞瘤真实世界数据。
- 采用调整Poisson模型比较各区域每10万居民手术率,并用灵活参数模型估计标准化生存。
主要发现
- 18–70岁患者治疗与生存无显著区域差异,全国中位标准化生存14.4个月(95%CI 13.6–15.2)。
- 71–89岁患者北部手术率比率为1.32(95%CI 0.99–1.77),术后放疗和替莫唑胺使用较少。
- 北部老年患者中位标准化生存4.5个月(95%CI 3.5–5.7),全国为7.7个月(95%CI 6.9–8.6)。
- 北部老年患者早期死亡率尤其高,但生存超过6个月者生存概率与其他区域相当。
关键数值与推荐
- 完整治疗包括手术切除、放疗(≤70岁≥55 Gy;>70岁≥30 Gy)和替莫唑胺。
- 生存标准化调整年龄、性别、年份及至治疗机构距离。
临床怎么用
- 老年胶质母细胞瘤患者手术选择需评估虚弱程度,并关注术后放化疗衔接以减少早期死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Surveillance of patient outcomes with real-world data is essential to uncover regional disparities in clinical practice or quality of care. This study explored survival differences among glioblastoma patients in Norway and investigated the role of demographic and treatment factors. METHODS: We analyzed real-world data from the Norwegian Cancer Registry on 1158 adults with histologically confirmed glioblastoma during 2019-2023. Surgical treatment rates per 100,000 inhabitants per region (South-East, West, Mid, North) were compared using adjusted Poisson models. Full treatment included surgical resection, radiotherapy (≥ 55 Gy for ≤ 70 years; ≥30 Gy for > 70 years), and temozolomide. Standardized survival was estimated with flexible parametric models, standardized for age, sex, year, and distances to treatment facilities. RESULTS: Patients from the North were older and lived further from treatment centers. For patients aged 18-70, treatment and survival did not significantly differ across regions; national median standardized survival was 14.4 months (95%CI:13.6-15.2). For elderly patients (71-89 years), the North demonstrated a higher surgical treatment rate (rate ratio = 1.32; 95%CI = 0.99-1.77), but lesser use of postoperative radiotherapy and temozolomide. Median standardized survival for elderly patients in the North was 4.5 months (95%CI: 3.5-5.7) versus 7.7 (6.9-8.6) months nationally. Early mortality was particularly high for elderly patients in the North, yet those surviving beyond six months matched other regions' survival probability. CONCLUSION: Lower glioblastoma survival in the North was associated with higher early mortality among elderly patients, likely due to selecting frailer patients for surgery, who less often subsequently received anti-neoplastic treatment.
引用
- Trewin-Nybråten CB, Lambert PC, Marienhagen K, et al. Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry. J Neurooncol. 2025. PMID: 40932639. doi:10.1007/s11060-025-05218-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。